Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

JNJ

Johnson & Johnson

Nov 21 • 04:00PM ET

203.90

+0.83 0.41 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: MRK PFE NVS AMGN BMY LLY GSK ABT MDT SYK

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM DGRO IWD

Scroll to Statements

Index	DJIA, S&P 500	P/E	19.68	EPS (ttm)	10.36	Insider Own	0.14%	Shs Outstand	2.41B	Perf Week	4.07%
Market Cap	491.26B	Forward P/E	17.72	EPS next Y	11.51	Insider Trans	-6.64%	Shs Float	2.41B	Perf Month	5.94%
Enterprise Value	518.49B	PEG	2.64	EPS next Q	2.53	Inst Own	74.40%	Short Float	0.81%	Perf Quarter	14.29%
Income	25.12B	P/S	5.33	EPS this Y	8.86%	Inst Trans	-0.16%	Short Ratio	2.30	Perf Half Y	33.32%
Sales	92.15B	P/B	6.19	EPS next Y	5.93%	ROA	13.54%	Short Interest	19.53M	Perf YTD	40.99%
Book/sh	32.95	P/C	26.47	EPS next 5Y	7.45%	ROE	33.62%	52W High	204.51 -0.30%	Perf Year	33.27%
Cash/sh	7.70	P/FCF	25.07	EPS past 3/5Y	-9.49% 0.55%	ROIC	21.16%	52W Low	140.68 44.94%	Perf 3Y	17.55%
Dividend Est.	5.19 (2.55%)	EV/EBITDA	16.64	Sales past 3/5Y	-1.79% 1.58%	Gross Margin	68.27%	Volatility	1.72% 1.54%	Perf 5Y	35.17%
Dividend TTM	5.08 (2.49%)	EV/Sales	5.63	EPS Y/Y TTM	71.07%	Oper. Margin	25.79%	ATR (14)	3.09	Perf 10Y	104.14%
Dividend Ex-Date	Nov 25, 2025	Quick Ratio	0.80	Sales Y/Y TTM	5.08%	Profit Margin	27.26%	RSI (14)	79.76	Recom	2.11
Dividend Gr. 3/5Y	5.43% 5.54%	Current Ratio	1.07	EPS Q/Q	91.19%	SMA20	5.89%	Beta	0.32	Target Price	206.45
Payout	84.80%	Debt/Eq	0.58	Sales Q/Q	6.77%	SMA50	8.30%	Rel Volume	1.55	Prev Close	203.07
Employees	139800	LT Debt/Eq	0.50	Earnings	Oct 14 BMO	SMA200	21.33%	Avg Volume	8.50M	Price	203.90
IPO	Sep 25, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.54% 1.00%	Trades		Volume	13,172,183	Change	0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$230
Oct-20-25	Upgrade	Daiwa Securities	Neutral → Outperform	$203
Oct-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$212
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy	$206
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175

Show Previous Ratings

Nov-21-25 01:32PM	Contineums MS drug falls short in Phase II trial (Clinical Trials Arena)
12:43PM	1 Reason Why Shares of Johnson & Johnson Are Surging This Month (Motley Fool)
10:29AM	Eli Lilly Touches $1 Trillion Market Cap on Booming Weight-Loss Drugs (The Wall Street Journal)
10:29AM	Eli Lilly Reaches $1 Trillion Market Cap on Booming Weight-Loss Drugs (The Wall Street Journal)
10:19AM	Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI (Zacks)
08:00AM	Loading…
08:00AM	This Medical Technology Leader Sees Profit Growth Topping 44% (Investor's Business Daily)
07:13AM	Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It? (Zacks)
Nov-20-25 01:10PM	Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio? (Zacks)
07:05AM	Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales (Zacks)
Nov-19-25 12:36PM	Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers (Fortune)
12:24PM	Why Johnson & Johnson's Share Price Is Popping This Month (Motley Fool)
10:52AM	Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study (Zacks)
10:38AM	Why GRAIL Stock Could Be Biotech's Next Big Breakout (MarketBeat)
09:08AM	AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell? (Zacks)
09:00AM	Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:53AM	Loading…
08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
08:02AM	Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine? (Zacks)
Nov-18-25 04:21PM	Why biotech and drug stocks are on the mend even though the rest of the market is hurting (MarketWatch)
11:03AM	J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B (Zacks)
10:07AM	3 Smart Defensive Stocks for an Uneasy Market (MarketBeat)
09:37AM	Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3 (Zacks)
06:30AM	Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion (The Daily Upside)
04:59AM	Johnson & Johnson to acquire Halda Therapeutics for $3.05bn (Pharmaceutical Business Review)
04:27AM	The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum (Zacks)
01:16AM	Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition (GuruFocus.com)
Nov-17-25 06:07PM	Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy (Business Wire)
04:22PM	Stock Market Today: Dow Skids, AI Play Dives As Peter Thiel Exits; Netflix Divvies Up Its Shares (Live Coverage) (Investor's Business Daily)
03:02PM	Stock Market Today: Dow Dips As Biotech Eyes Entry; Why Netflix Went From $1,100 To $111 (Live Coverage) (Investor's Business Daily)
01:20PM	Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion (Barrons.com)
11:02AM	Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment (Investor's Business Daily)
10:43AM	Loading…
10:43AM	J&J to acquire Halda, Sinclair takes 8.2% stake in E.W. Scripps (Yahoo Finance Video)
08:58AM	BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ (Zacks)
08:40AM	Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus (Zacks)
08:29AM	Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion (The Wall Street Journal)
08:05AM	New long-term data reinforces TREMFYA (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis (PR Newswire)
08:00AM	Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics (Business Wire)
07:08AM	Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ (Zacks)
Nov-15-25 10:01PM	Johnson & Johnson (JNJ) Emerges as Scotiabank's Top Pick for Curative Treatments (Insider Monkey)
Nov-14-25 04:02PM	Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail (Investor's Business Daily)
12:38PM	Bristol Myers Shares Sink on Yet Another Trial Failure (Barrons.com)
12:34PM	Top Stock Movers Now: StubHub, DoorDash, Netflix, and More (Investopedia)
09:38AM	Bristol Myers Slumps After Its Heart Condition Study Gets The Boot (Investor's Business Daily)
07:59AM	Pharma ETFs in Spotlight Following Robust Q3 Earnings Results (Zacks)
Nov-13-25 12:09PM	Jim Cramer Notes Johnson & Johnson is "Really Bearing Down on High-Growth Pharma" (Insider Monkey)
11:36AM	Jim Cramer Praises Johnson & Johnson (JNJ)'s Drugs (Insider Monkey)
11:30AM	Why Is Johnson & Johnson (JNJ) Up 1.7% Since Last Earnings Report? (Zacks)
09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
08:07AM	Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month (Zacks)
05:04AM	2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon (Motley Fool)
03:55AM	2 Strong Healthcare Stock Picks for Dividend Investors (Motley Fool)
Nov-12-25 04:30PM	BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
03:20PM	Walt Disney and 15 More Non-AI Stocks Worth a Look (Barrons.com)
12:55PM	IBD Stock Of The Day BeOne Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
12:26PM	Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains (Zacks)
11:51AM	How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance? (Zacks)
11:01AM	Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. (Motley Fool)
10:46AM	'Michael Burry Scared Me,' Says 25-Year-Old Who Bought Nvidia Dip For $101'SOLD IT ALL!!' Over AI Bubble Fears, Now Sitting On Cash Awaiting Crash (Benzinga)
08:46AM	Healthcare breakout means investors should add exposure to the sector, says Strategas (MarketWatch)
06:53AM	J&J's MedTech Unit Sales Improve: Will the Momentum Last? (Zacks)
Nov-11-25 09:30AM	Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest? (Zacks)
Nov-10-25 07:00AM	Black Hair Accessories Brand Targets $50M Revenue By 2030 With New Products, Market Expansion (Black Enterprise)
04:15AM	Got $1,000? Here Are the Smartest Dividend Stocks to Start With. (Motley Fool)
Nov-07-25 11:00AM	J&Js Darzalex gains first FDA approval in smouldering multiple myeloma (Pharmaceutical Technology)
09:48AM	Is a Market Correction Coming? Better Grab 5 of the Safest Dividend Kings Now (24/7 Wall St.)
Nov-06-25 05:07PM	DARZALEX FASPRO is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma (PR Newswire)
12:34PM	J&Js Caplyta wins MDD approval to extend revenue horizon (Pharmaceutical Technology)
10:17AM	Cramer's Mad Dash: Johnson & Johnson (CNBC TV)
07:51AM	AstraZeneca CEO bullish on record revenue numbers and US growth (Yahoo Finance Video)
07:30AM	FDA approval of CAPLYTA (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder (PR Newswire)
06:03AM	J&J brain drug acquired in $14.6B buyout cleared for broader use (BioPharma Dive)
Nov-05-25 04:50PM	Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference (Business Wire)
04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
02:38PM	This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Heres Why. (Barrons.com)
12:00PM	This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. (Barrons.com)
09:00AM	Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Nov-04-25 10:31AM	Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View (Zacks)
07:25AM	Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn (Pharmaceutical Technology)
06:30AM	Kimberly-Clark Takeover Offers $48 Billion of Pain Relief to Tylenol-Maker Kenvue (The Daily Upside)
06:14AM	Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal (GuruFocus.com)
02:00AM	Alvotech faces FDA setback for its Simponi biosimilar AVT05 (Pharmaceutical Technology)
Nov-03-25 07:24PM	Analyst Report: Kenvue Inc. (Morningstar Research)
04:54PM	Kimberly-Clark Stock Takes Biggest One-Day Hit Since Black Monday (The Wall Street Journal)
03:45PM	Kimberly-Clark to Buy Tylenol Maker Kenvue. Why the Stock Market Hates the Deal. (Barrons.com)
03:41PM	Dear Kenvue Stock Fans, Mark Your Calendars for November 6 Upcoming earnings (Barchart)
03:00PM	Is the End of the Line Near for Kenvue? (The Wall Street Journal)
02:23PM	Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger (TheStreet)
02:13PM	Kimberly-Clark bets $40 billion on Kenvue despite Tylenol controversy (Reuters Videos)
11:58AM	Kimberly-Clark to Buy Kenvue in $48.7 Billion Deal (GuruFocus.com)
11:33AM	Tylenol trust crisis: Trump, RFK Jr. and Texas lawsuits slam Kenvue (TheStreet)
11:15AM	Kimberly-Clark Stock Heads for Biggest One-Day Drop Since Black Monday (The Wall Street Journal)
10:18AM	Tylenol maker Kenvue leads S&P 500, boosted by $48.7 billion Kimberly-Clark deal (MarketWatch)
09:35AM	Kimberly-Clark to Buy Tylenol Maker Kenvue. Why Kimberly-Clark Stock Is Tanking. (Barrons.com)
09:16AM	Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger (The Guardian)
08:47AM	Kimberly-Clark to Buy Tylenol Maker Kenvue in $48.7B Deal. Kimberly-Clark Stock Tanks. (Barrons.com)
08:43AM	Kimberly-Clark to buy Kenvue, maker of Tylenol, in $48 billion deal (USA TODAY)
08:19AM	Kimberly-Clark buys Tylenol maker Kenvue for more than $48 billion (Quartz)
08:19AM	Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue (The Wall Street Journal)
07:21AM	Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal (Associated Press Finance)
06:47AM	Kimberly-Clark to Acquire Kenvue (WWD)
06:15AM	Will President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks? (Motley Fool)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JOHNSON & JOHNSON	10% Owner	Nov 12 '25	Sale	10.00	1,000	10,000	4,049,898	Nov 14 03:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 06 '25	Sale	10.21	52,332	534,310	4,051,098	Nov 10 03:28 PM
JOHNSON & JOHNSON	10% Owner	Nov 07 '25	Sale	10.00	200	2,000	4,050,898	Nov 10 03:28 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Oct 17 '25	Option Exercise	157.92	21,721	3,430,180	32,379	Oct 20 07:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Oct 17 '25	Sale	192.71	21,721	4,185,793	10,658	Oct 20 07:13 PM
REED JOHN C	Officer	Oct 17 '25	Proposed Sale	192.71	21,721	4,185,794		Oct 17 10:23 AM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Option Exercise	101.87	56,471	5,752,701	234,484	Sep 05 06:00 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Sale	177.81	56,471	10,040,883	178,013	Sep 05 06:00 PM
Taubert Jennifer L	Officer	Sep 04 '25	Proposed Sale	177.81	56,471	10,040,904		Sep 04 02:37 PM
Forminard Elizabeth	Executive VP, General Counsel	Aug 29 '25	Option Exercise	115.67	11,521	1,332,634	22,423	Sep 03 05:13 PM
Forminard Elizabeth	Officer	Aug 29 '25	Proposed Sale	177.20	9,570	1,695,806		Aug 29 03:36 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Option Exercise	101.87	125,824	12,817,691	401,791	Aug 25 07:12 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Sale	179.21	125,824	22,548,655	275,967	Aug 25 07:12 PM
Duato Joaquin	Officer	Aug 22 '25	Proposed Sale	180.03	125,824	22,652,724		Aug 22 01:58 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Option Exercise	101.87	16,820	1,713,453	30,820	Aug 18 06:19 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Sale	176.91	16,820	2,975,571	14,000	Aug 18 06:19 PM
Wolk Joseph J	Officer	Aug 15 '25	Proposed Sale	176.91	16,820	2,975,571		Aug 15 03:57 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Jul 17 '25	Sale	163.55	19,137	3,129,830	10,658	Jul 18 04:12 PM
REED JOHN C	Officer	Jul 17 '25	Proposed Sale	163.55	19,137	3,129,831		Jul 17 04:05 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '25	Option Exercise	0.00	25,255	0	40,797	May 05 05:10 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience